PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma

Background: After surgical resection in adrenocortical carcinoma (ACC), mitotane is often used as adjuvant therapy. However, mitotane can cause adverse effects, such as inducing hypercholesterolemia by stimulating HMG-CoA reductase. In addition, mitotane is a strong CYP3A4 inducer which presents a c...

Full description

Saved in:
Bibliographic Details
Published in:J Endocr Soc
Main Authors: Aurora, John A, Erenler, Feyza, Matta, Stephany, Lechan, Ronald M
Format: Artigo
Language:Inglês
Published: Oxford University Press 2021
Subjects:
Cardiovascular Endocrinology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089732/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.634
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items